Secretory Proteins / edited by Rossen Donev

Intro -- Secretory Proteins -- Copyright -- Contents -- Contributors -- Chapter One: Proprotein convertases regulate trafficking and maturation of key proteins within the secretory pathway -- 1. Introduction -- 2. Basic PCs -- 2.1. Biochemistry -- 2.1.1. Consensus sequence -- 2.1.2. Cellular localization and organ expression -- 2.1.3. Inhibitors -- 2.2. Structure of basic proprotein convertases -- 2.3. Cellular substrates -- 2.3.1. Pro-hormones -- 2.3.2. Neuropeptides -- 2.3.3. Growth factors -- 2.3.4. Extracellular matrix (ECM)-related proteins -- 2.3.5. Other PCs substrates.

2.3.6. PCs as biochemistry tools -- 2.4. Pathogen substrates -- 2.4.1. Viruses -- 2.4.2. Bacteria toxins of anthrax -- 3. SKI-1/S1P -- 3.1. Biochemistry -- 3.1.1. Cellular localization and organ expression -- 3.1.2. Inhibitors -- 3.1.3. Consensus sequence -- 3.2. Structure -- 3.3. Cellular substrates -- 3.3.1. Transcription factors -- 3.3.2. GlcNAc-phosphotransferase -- 3.3.3. Pro-renin receptor -- 3.3.4. Fam20C -- 3.4. Pathogen substrates -- 3.4.1. Mammarenaviruses -- 3.4.2. Bunyaviruses -- 3.4.3. Other viruses -- 3.4.3.1. SARS-CoV-2 -- 4. PCSK9 -- 5. Conclusions -- Acknowledgments -- References.

Chapter Two: Exploring the macromolecules for secretory pathway in cancer disease -- 1. Introduction -- 2. Secretory proteins -- 2.1. Role of secreted proteins in tumor cell proliferation and survival -- 2.2. Effect of secretory proteins on tumor cell motility and metastasis -- 2.3. Pathways associated with secretory proteins -- 3. The cancer secretome -- 4. Methods for analyzing secretory proteins -- 4.1. Genome-based computational prediction -- 4.2. Proteomic approaches -- 4.3. Gel-based proteomics approach -- 4.4. Gel-free MS-based technologies -- 4.5. SELDI-TOF-MS -- 5. Tumor cell secretome.

5.1. Secretome in breast cancers -- 6. Effect of therapy-induced tumor secretome on tumor microenvironment -- 7. Cancer secretome from heterotypic cells -- 8. The angiogenesis-derived secretome -- 8.1. Secretome from angiogenesis -- 9. Conclusion -- Acknowledgment -- References -- Chapter Three: Current and emerging biomarkers in ovarian cancer diagnosis -- CA125 and beyond -- 1. Introduction -- 2. Ovarian cancer and its pathogenesis -- 2.1. Genetic drivers of ovarian cancer -- 2.2. Ovarian cancer classification and histopathology -- 2.3. Molecular pathways involved in the development of OC.

3. Challenges/limitations associated with OC diagnosis -- 4. Molecular diagnosis of OC -- 4.1. Secretory protein biomarkers in the diagnosis and prognosis of OC -- 4.1.1. Cancer antigen 125 or carbohydrate antigen 125 (CA125) -- 4.1.2. Human epididymis secretory protein 4 (HE4) -- 4.1.3. Osteopontin (OPN) -- 4.1.4. Kallikreins (KLKs) -- 4.1.5. Vascular endothelial growth factor (VEGF) -- 4.1.6. Human Prostasin (PSN) -- 4.1.7. Transthyretin (TTR) -- 4.1.8. Risk of ovarian malignancy algorithm (ROMA) -- 4.2. Emerging potential of non-protein secretory biomarkers for OC detection -- 4.2.1. microRNAs.

Medienart:	E-Book

Erscheinungsjahr:	2023
Erschienen:	Cambridge, MA: Academic Press ; 2023

Reihe:	Advances in protein chemistry and structural biology - v. 133

Sprache:	Englisch

Beteiligte Personen:	Donev, Rossen [HerausgeberIn]

Links:	search.ebscohost.com [lizenzpflichtig]

ISBN:	978-0-443-15821-6 0-443-15821-5

Themen:	Glands Proteins

Umfang:	1 Online-Ressource

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	188263523X